<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-159440</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant syndrome: a case report</dc:title>
<dc:description xml:lang="en">Neuroleptics are a group of drugs widely used in the treatment of psychotic symptoms. Among their adverse effects is the ability to trigger a neuroleptic malignant syndrome (NMS). The diagnosis of NMS is determined by exclusion, and its initial therapeutic management should be the withdrawal of neuroleptics, the administration of benzodiazepines, and electroconvulsive therapy (ECT). ECT is an effective treatment in these patients, and in those cases with a poor response to treatment with antipsychotic drugs. A review is presented on the treatment options and anaesthetic implications of ECT used to handle a patient diagnosed with paranoid schizophrenia in the context of NMS (AU)</dc:description>
<dc:creator>López Álvarez, S</dc:creator>
<dc:creator>Gestal Vázquez, M</dc:creator>
<dc:creator>Casas Reza, P</dc:creator>
<dc:creator>Diéguez García, P</dc:creator>
<dc:creator>Outeiro Rosato, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los neurolépticos son un grupo de medicamentos ampliamente empleados en el tratamiento de cuadros psicóticos, entre sus efectos adversos cabe destacar la posibilidad de desencadenar un síndrome neuroléptico maligno (SNM). El diagnóstico del SNM se determina por exclusión y su manejo terapéutico inicial será la retirada de los neurolépticos junto a la administración de benzodiacepinas y terapia electroconvulsiva (TEC). La TEC representa una efectiva opción terapéutica en estos pacientes así como en aquellos casos que se obtenga una respuesta escasa al manejo con medicamentos antipsicóticos. Revisamos las alternativas terapéuticas y las implicaciones anestésicas que conlleva manejar un paciente programado para TEC, diagnosticado de esquizofrenia paranoide, en el contexto de SNM (AU)</dc:description>
<dc:source>Rev Esp Anestesiol Reanim;64(2): 105-107, feb. 2017.</dc:source>
<dc:identifier>ibc-159440</dc:identifier>
<dc:title xml:lang="es">Rocuronio-sugammadex para el manejo de la terapia electroconvulsiva en el síndrome neuroléptico maligno, a propósito de un caso</dc:title>
<dc:subject>^d9658^s22078</dc:subject>
<dc:subject>^d13776^s22073</dc:subject>
<dc:subject>^d31698^s22073</dc:subject>
<dc:subject>^d9658^s22044</dc:subject>
<dc:subject>^d4637^s22045</dc:subject>
<dc:subject>^d14542^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d30903^s22073</dc:subject>
<dc:subject>^d9650^s22057</dc:subject>
<dc:subject>^d9650^s22012</dc:subject>
<dc:subject>^d54179^s22073</dc:subject>
<dc:subject>^d4637^s22074</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d4634^s22074</dc:subject>
<dc:subject>^d24841^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201702</dc:date>
</metadata>
</record>
</ibecs-document>
